What Do Investors Need to Know About Your Dealings With the FDA? Practice Pointers for Life Science Companies
Part of the Pepper Hamilton Health Sciences Speaker Series.
Heightened scrutiny of SEC disclosures regarding the drug development process has left some companies and their executives in the crosshairs of the SEC and shareholders. In a March 2015 speech, the SEC’s Enforcement Director stated, “accuracy of reporting in your dealings with the FDA is critical to getting investors the information they need. FDA dealings and approvals are the lifeblood of your business and are so important to investment decisions.”
Join Pepper Hamilton attorneys Aline Fairweather, Scott R. Jones, Sharon R. Klein and Pamela S. Palmer as they discuss the recent uptick in SEC enforcement actions and shareholder lawsuits premised on misrepresentations or omissions regarding the drug development process and the specific types of disclosures that are garnering heightened scrutiny.
This webinar is approved for one general MCLE credit in California.
There is no cost to register.
This webinar is sponsored by Pepper Hamilton's Health Sciences Department, a team of 110 attorneys who collaborate across disciplines to solve complex legal challenges confronting clients throughout the health sciences spectrum.